Clinical Trials Sponsored by Meyer Pharmaceuticals

Total 19683 results

Ligand Pharmaceuticals
CyDex Pharmaceuticals, Inc.

Withdrawn

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Contrast-induced Nephropathy
Paratek Pharmaceuticals Inc
Novartis Pharmaceuticals

Terminated

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (CSSI)

Skin Diseases, Infectious

United States
Vertex Pharmaceuticals Incorporated
Janssen Pharmaceuticals

Terminated

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Hepatitis C

United States, United Kingdom, Spain, Belgium, Italy, Germany
Eleison Pharmaceuticals LLC.
Threshold Pharmaceuticals

Completed

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

Neoplasms | Lymphoma

United Kingdom
Nucorion Pharmaceuticals, Inc.
Ligand Pharmaceuticals

Completed

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Chronic Hepatitis B

United States
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Hepatitis C, Chronic

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Liver Transplantation | Hepatitis | Carcinoma, Hepatocellular | Cholestasis

United States, Germany
Virginia Moyer
Agency for Healthcare Research and Quality (AHRQ)

Completed

Safe Passages: Ensuring Quality Transitions From NICU (Neonatal Intensive Care Unit) to Ambulatory Care

Infant, Premature, Diseases

United States
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Institut Bergonié
Bristol-Myers Squibb; Amgen; Aventis Pharmaceuticals; Sanofi-Synthelabo; Chugai Pharmaceutical

Completed

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment (PHRC2003)

Digestive System Diseases | Lymphoma | Ovarian Diseases | Pulmonary Disease | Bladder Disease | Prostatic Disease

France
Foresee Pharmaceuticals Co., Ltd.
QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Puberty; Precocious, Central

United States, China, Taiwan, Puerto Rico
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
Assistance Publique - Hôpitaux de Paris
Action Research Group; Bristol-Meyers Squibb & Pfizer

Completed

Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS)

Symptomatic Aortic Stenosis | Eligible for Transcatheter Aortic Valve Replacement

France, Germany, Italy, Spain
Universidad de Valparaiso
Hospital Dr. Gustavo Fricke; Fundación Dr. Jorge Kaplan Meier

Completed

Technological Platforms and Telerehabilitation in Heart Surgery

Cardiovascular Diseases | Cardiac Surgery

Chile
IRCCS Fondazione Stella Maris
Azienda USL Toscana Nord Ovest; University of Dublin, Trinity College; Meyer...

Recruiting

Biomarkers in Rett Syndrome (BIRS)

Rett Syndrome

Italy, Ireland
Fondazione Don Carlo Gnocchi Onlus
Meyer Children's Hospital IRCCS; Fondazione Don Carlo Gnocchi ONLUS - Centro...

Recruiting

Mealtime Assessment Scale-p Adaptation and Validation

Dysphagia

Italy
Università degli Studi di Ferrara
Azienda Ospedaliero, Universitaria Pisana; Rare Partners srl Impresa Sociale; Azienda Ospedaliero, Universitaria Meyer

Recruiting

Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) (THALA-RAP)

Beta-Thalassemia

Italy
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Recruiting

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Major Depressive Disorder

United States
EMET Pharmaceuticals, LLC
Eagle Pharmaceuticals, Inc.

Completed

A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

Mild to Moderate Ulcerative Colitis
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Completed

Mass Balance Study of NV-5138 in Healthy Male Subjects.

Healthy Volunteers

United Kingdom
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Prostate Cancer

Korea, Republic of
Neurotech Pharmaceuticals

Not yet recruiting

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Macular Telangiectasia Type 2

United States
Regeneron Pharmaceuticals

Not yet recruiting

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals

Recruiting

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Food Allergy

United States
Arrowhead Pharmaceuticals

Recruiting

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)

Severe Hypertriglyceridemia

United States
Acumen Pharmaceuticals

Recruiting

A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD) (ALTITUDE-AD)

Alzheimer Disease

United States, France, Italy, Germany, Spain, Canada, Poland, United Kingdom
Gilgamesh Pharmaceuticals

Recruiting

A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

Major Depressive Disorder

United Kingdom
Ferring Pharmaceuticals

Recruiting

A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons

Inflammatory Gastrointestinal Diseases

Germany
Novilla Pharmaceuticals

Not yet recruiting

Treatment of Topical Ketorolac Gel in Acute Gouty Flare

Acute Pain | Gout Flare | Acute Gouty Arthritis

Australia
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Alnylam Pharmaceuticals

Recruiting

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (KARDIA-3)

Hypertension | High Cardiovascular Risk

United States
Ferring Pharmaceuticals

Recruiting

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Gilgamesh Pharmaceuticals

Recruiting

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Major Depressive Disorder

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, Spain, Malaysia, France, Taiwan, Italy, Poland, United States, Thailand, United Kingdom, Turkey, Belgium, Czechia
Regeneron Pharmaceuticals

Recruiting

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Healthy Volunteers

New Zealand
Currax Pharmaceuticals

Recruiting

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

Obesity

United States
SciClone Pharmaceuticals

Not yet recruiting

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Neuroblastoma
Regeneron Pharmaceuticals

Recruiting

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations (ENSEMBLE)

Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF) | Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes

United States
Vanda Pharmaceuticals

Recruiting

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Motion Sickness

United States
MinaPharm Pharmaceuticals

Recruiting

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole (CIPRO-001)

Surgical Site Infections

Egypt
Jazz Pharmaceuticals

Recruiting

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex (EpiCom)

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

United States, United Kingdom, Poland
Ferring Pharmaceuticals

Recruiting

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection (CDI-SCOPE)

Clostridium Difficile Infection Recurrence

United States
Quoin Pharmaceuticals

Recruiting

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Netherton Syndrome

United States
Alnylam Pharmaceuticals

Recruiting

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

Canada, United States
CStone Pharmaceuticals

Not yet recruiting

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Extranodal NK/T-cell Lymphoma
ASLAN Pharmaceuticals

Recruiting

Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Atopic Dermatitis

United States, Canada
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, United Kingdom

Clinical Trials Sponsored by Meyer Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations